Bionano Genomics Symposium to Illuminate Cutting-Edge Genomic Research
Bionano Genomics, Inc. is poised to host its 2024 Symposium, a pivotal virtual event scheduled from January 22 to 25. The symposium is set to feature a robust lineup of 33 oral presentations by 26 distinguished customers hailing from North America, Asia, and Europe. This event is anticipated to serve as a cornerstone for the dissemination of knowledge regarding the applications of optical genome mapping (OGM) across a spectrum of research domains, including but not limited to cancer, cell and gene therapy, and genetic diseases.
The symposium is meticulously organized to be a nexus for the exchange of advancements in translational research. Each day is meticulously planned to include user presentations, live panel discussions, and interactive Q&A sessions. Additionally, a virtual exhibition hall will display 69 scientific posters, providing a comprehensive view of the latest research. Erik Holmlin, PhD, the President and CEO of Bionano Genomics, has expressed his enthusiasm for the symposium, underscoring the unique opportunity it presents for the OGM community to converge and share their research progress.
A highlight of the symposium will be the unveiling of a new product by Bionano on the second day, which is anticipated to significantly enhance cytogenetics and structural variant analysis. This innovation underscores the company’s unwavering commitment to propelling research advancements and refining clinical and translational research workflows. The symposium will also host specialized sessions focusing on heme malignancy research and solid tumor analysis, with updates on OGM adoption by global consortia and fresh data from researchers addressing constitutional and rare diseases. Alka Chaubey, PhD, FACMG, the Chief Medical Officer at Bionano, has noted the improvements since the last symposium and the superior quality of the presentations slated for this year.
The event will commence daily at 7:00 am PST, with sessions spanning approximately three hours. Following the scientific presentations, the speakers will engage in a live panel discussion moderated by Dr. Chaubey. The symposium is designed to offer attendees an invaluable opportunity to learn from their peers, expand their professional network, and explore new products and scientific research.
The inaugural day will be dedicated to “New Standards in Hematological Malignancies,” featuring speakers from prestigious institutions such as Saint John Regional Hospital, Johns Hopkins University School of Medicine, and the University of Texas MD Anderson Cancer Center. The discussions will encompass a range of topics, from the clinical research applications of OGM in cancer cytogenetics to the latest advancements in informatics and software for OGM data analysis.
The subsequent day, themed “New Frontiers in Oncology,” will persist in highlighting the profound impact of OGM on cancer research. The symposium is shaping up to be an enlightening and collaborative event, uniting a diverse assembly of researchers and professionals from various fields.
The 2024 Bionano Genomics Symposium is set to mark a significant milestone for the scientific community. It aims to provide a dynamic platform for the exchange of knowledge and the most recent research findings in the field of genome mapping. The event is not merely about unveiling new products; it is about offering a panoramic view of the present state and prospective trajectories of OGM in research. By fostering collaboration and dialogue among experts, Bionano Genomics is making a substantial contribution to the advancement of genomic science and the comprehension of complex diseases. The symposium stands as a testament to the company’s dedication to innovation and the relentless pursuit of knowledge in the expansive realm of genomics.
Source link
